Editorials in 2007

Filter By:

Article Type
Year

  • Interferon (IFN)-α has reigned supreme for decades as biotech's blockbuster antiviral. That looks set to change with a raft of antibody and nucleic acid therapies progressing through the pipeline.

    Editorial

  • Animal vaccines prevent disease but founder because of political motivations.

    Editorial

  • In Europe, no one apparently wants to listen if you have good news about genetically modified organisms (GMOs).

    Editorial

  • Controversial US patent system reforms and rule changes currently being proposed spell big trouble for biotech.

    Editorial

  • The newly passed US Food and Drug Administration's (FDA) Amendments Act (FDAAA) sets the stage for key improvements to postmarketing surveillance as well as the preapproval process.

    Editorial

  • To what extent did the French government's failure to publicly disclose the exact location of field trials contribute to the suicide of a farmer hounded by anti-GM activists?

    Editorial

  • A meeting earlier this year in Toronto offered a unique forum for showcasing biotech firms from emerging economies.

    Editorial

  • More definitive answers about the death of a woman in an adeno-associated virus (AAV) gene therapy trial for arthritis must await a meeting of the Recombinant DNA Advisory Committee (RAC) later this month.

    Editorial

  • The example set by leading proteomics laboratories will be a major factor in determining the successful implementation of new reporting guidelines in the wider community.

    Editorial

  • Despite hand-wringing over the patenting of a minimized organism, both patents and open-source approaches will be needed to promote innovation and research progress in synthetic biology.

    Editorial

  • The biotech industry's trade organizations need to better represent the concerns of their rank and file.

    Editorial

  • Is it a bird? Is it a plane? No, it's Boston's Supercluster!

    Editorial

  • Almost six years after the anthrax attacks, the US BioShield Program has singularly failed to add new products to the nation's stockpile.

    Editorial

  • The thinking behind the US Food and Drug Administration's (FDA) draft guidance on financial conflicts of interest for outside experts is deeply flawed.

    Editorial

  • In view of concerns about safety, could Amgen's aggressive promotion of erythropoietin (EPO) have jeopardized its billion-dollar franchise?

    Editorial

  • The nonprofit Pew Initiative on Food and Biotechnology is closing, but the need for an independent and neutral body to facilitate dialog on US biotech policy has never been greater.

    Editorial

  • A think tank and an investment bank have proposed solutions to address the lack of funding to carry biotech companies through the early stages of clinical development.

    Editorial